Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer
6011.5000 -59.50 (-0.98%)
NSE Jan 23, 2026 15:48 PM
Volume: 460.5K
 

6011.50
-0.98%
Motilal Oswal
Revenues grew 13% YoY to INR19.6b (our est: INR19.9b) for the quarter. The gross margin expanded 420bp YoY to 67.2%. This was largely owing to a superior product mix and lower raw material costs. The EBITDA margin expanded at a lower rate of 300bp YoY to 43.5% (our est: 40.9%) due to higher employee costs (+60bps as a percentage of sales) and other expenses (+60bps as a percentage of sales) EBITDA was up 22% to INR8.5b (our est: INR8.1b) for the quarter YoY. Adjusted for INR196m in forex gains, PAT grew at a lower rate of 13% YoY to...
Divi's Laboratories Ltd. is trading below all available SMAs
More from Divi's Laboratories Ltd.
Recommended